Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CIHR-334091 | Other Grant/Funding Number | Canadian Institutes of Health Research |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
| Estrie University Integrated Health and Social Services Center - University Hospital of Sherbrooke | OTHER |
| CISSS de Laval | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Anxiety disorders are the most common mental disorders in community settings, and they are associated with significant psychological distress, functional and social impairment. Although pharmacological and psychological treatments for anxiety and depression have existed for several years now, only a minority of anxiety disorder sufferers are treated according to guidelines. Cognitive behavior therapy (CBT) is the most consistently efficacious psychological treatment for anxiety disorders, but implementation of CBT in primary care is challenging due to limited resources. Recent studies indicate that transdiagnostic group CBT for multiple anxiety disorders could be a promising alternative to individual CBT in primary care. The aim of the study is to examine the effectiveness of group CBT for anxiety disorders as a complement to usual care. The clinical trial will be conducted in three Health and Social Services Centers in the province of Québec (i.e. Sherbrooke, Laval and Québec). Patients will be French-speaking adults with anxiety disorders, and they will be randomly assigned to one of two treatment conditions: a) Transdiagnostic group CBT (12 weekly 2-hour sessions), b) usual care. The transdiagnostic group CBT will be offered as a differed intervention to participants in the usual care group after the 8-month follow up. Participants in both study arms will undergo a baseline clinical evaluation as well as outcome assessment interviews at post-treatment, 4, 8, and 12 month follow-up time-points. The primary study results will include improvement on a questionnaire on anxiety symptoms. Widespread implementation of group CBT could lead to better outcomes for a large number of patients living with anxiety.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Transdiagnostic CBT | Experimental | Group psychotherapy according to the Transdiagnostic Cognitive-Behavioral Therapy treatment protocol (Norton, 2012) |
|
| Treatment-as-usual | No Intervention | Treatment-as-usual and a differed intervention (if desired by participants) after the 8-month follow up. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transdiagnostic Cognitive-Behavioral Therapy | Behavioral | Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Beck Anxiety Inventory (BAI) | Baseline and post-treatment; within two weeks after the 12th treatment session, based on the timeframe of the intervention group (treatment completion) | |
| Change in Clinical Severity Rating from the Anxiety Disorders Interview Schedule for DSM-5 - Adult Version (ADIS-5) | Baseline and post-treatment; within two weeks after the 12th treatment session, based on the timeframe of the intervention group (treatment completion) (Outcome 2 added 2017-12-12) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Beck Anxiety Inventory (BAI) | Baseline, post-treatment, 4-month, 8-month and 12-month follow-ups | |
| Change in Clinical Severity Rating from the Anxiety Disorders Interview Schedule for DSM-5 - Adult Version (ADIS-5) | Baseline, post-treatment and 8-month follow-ups |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pasquale Roberge, Ph.D. | Université de Sherbrooke | Principal Investigator |
| Martin D. Provencher, Ph.D. | Laval University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre intégré de santé et de services sociaux de Laval | Laval | Quebec | H7M3L9 | Canada | ||
| Centre intégré universitaire de santé et de services sociaux de l'Estrie |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30285672 | Background | Roberge P, Provencher MD, Gosselin P, Vasiliadis HM, Gaboury I, Benoit A, Antony MM, Chaillet N, Houle J, Hudon C, Norton PJ. A pragmatic randomized controlled trial of group transdiagnostic cognitive-behaviour therapy for anxiety disorders in primary care: study protocol. BMC Psychiatry. 2018 Oct 3;18(1):320. doi: 10.1186/s12888-018-1898-1. | |
| 37291599 |
| Label | URL |
|---|---|
| BMC Psychiatry | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016584 | Panic Disorder |
| D000379 | Agoraphobia |
| D000072861 | Phobia, Social |
| D000098647 | Generalized Anxiety Disorder |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
| D010698 | Phobic Disorders |
Not provided
Not provided
| Integrated University Health and Social Services Center of the Capitale-Nationale | OTHER |
Not provided
Not provided
Not provided
Not provided
| Change in Panic Disorder Severity Scale (Self-Report) | Baseline, post-treatment, 4-month, 8-month and 12-month follow-ups |
| Change in Mobility Inventory for Agoraphobia | Baseline, post-treatment, 4-month, 8-month and 12-month follow-ups |
| Change in Penn State Worry Questionnaire | Baseline, post-treatment, 4-month, 8-month and 12-month follow-ups |
| Change in Social Phobia Inventory | Baseline, post-treatment, 4-month, 8-month and 12-month follow-ups |
| Change in Patient Health Questionnaire (PHQ-9) | Baseline, post-treatment, 4-month, 8-month and 12-month follow-ups |
| Change in EuroQol (EQ-5D-5L) | Baseline, post-treatment, 4-month, 8-month and 12-month follow-ups |
| Change in Administrative databases records | Beneficiary registry (sex, birthdate, and death registry), Med-Écho hospitalizations (diagnosis, procedures), medical services (physician, diagnosis, acts, services) and pharmaceutical services (medication, dose, duration). | Starting 12 months prior to participant enrollment up to the 12-month follow-up |
| Change in Anxiety Disorder Diagnostic Questionnaire - weekly version (ADDQ-W) | ADDQ-W administered weekly over the course of the 12 weekly group therapy sessions to assess change in anxiety severity. |
| Sherbrooke |
| Quebec |
| J1G1B1 |
| Canada |
| Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale | Québec | G1C3S2 | Canada |
| Chapdelaine A, Vasiliadis HM, Provencher MD, Norton PJ, Roberge P. Moderators of the cost-effectiveness of transdiagnostic CBT for anxiety disorders over an 8-month time horizon using a net-benefit regression framework. BMC Health Serv Res. 2023 Jun 8;23(1):596. doi: 10.1186/s12913-023-09468-7. |